@article{3107830,
    title = "Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients",
    author = "Delcroix, M. and Staehler, G. and Gall, H. and Grünig, E. and Held, M. and Halank, M. and Klose, H. and Vonk-Noordegraaf, A. and Rosenkranz, S. and Pepke-Zaba, J. and Opitz, C.F. and Gibbs, J.S.R. and Lange, T.J. and Tsangaris, I. and Huscher, D. and Pittrow, D. and Olsson, K.M. and Hoeper, M.M.",
    journal = "The European respiratory journal",
    year = "2018",
    volume = "52",
    number = "5",
    publisher = "European Respiratory Society",
    doi = "10.1183/13993003.00248-2018",
    keywords = "brain natriuretic peptide, adult;  aged;  Article;  atrial fibrillation;  cardiac index;  chronic thromboembolic pulmonary hypertension;  comorbidity;  controlled study;  diabetes mellitus;  disease assessment;  endarterectomy;  female;  follow up;  heart right atrium pressure;  high risk population;  human;  intermediate risk population;  low risk population;  major clinical study;  male;  middle aged;  mortality risk;  oxygen saturation;  predictive value;  priority journal;  prognosis;  risk assessment;  risk factor;  six minute walk test;  survival analysis;  survival rate;  survival time;  World Health Organization Functional Class;  chronic disease;  complication;  epidemiology;  Europe;  lung embolism;  medical society;  mortality;  pathophysiology;  practice guideline;  procedures;  pulmonary hypertension;  register;  risk assessment;  validation study;  very elderly, Aged;  Aged, 80 and over;  Chronic Disease;  Europe;  Female;  Humans;  Hypertension, Pulmonary;  Male;  Middle Aged;  Practice Guidelines as Topic;  Prognosis;  Pulmonary Embolism;  Registries;  Risk Assessment;  Societies, Medical;  Survival Analysis",
    abstract = "Abbreviated versions of the risk stratification strategy of the European Society of Cardiology (ESC)/European Respiratory Society (ERS) pulmonary hypertension guidelines have been recently validated in patients with pulmonary arterial hypertension. We aimed to investigate their prognostic value in medically treated chronic thromboembolic pulmonary hypertension (CTEPH) patients from the COMPERA registry, which collects six variables of interest (World Health Organization Functional Class, 6-min walk distance, brain natriuretic peptide, right atrial pressure, cardiac index and mixed venous oxygen saturation). We included patients with at least one follow-up visit, no pulmonary endarterectomy and at least three of the six variables available, and classified the patients into low-, intermediate- and high-risk groups. As a secondary analysis, the number of noninvasive low-risk criteria was counted. The association between risk assessment and survival was evaluated. Data from inclusion and follow-up (median 7 months) visits were available for 561 and 231 patients, respectively. Baseline 1- and 5-year survival estimates were significantly different (p<0.0001) in the baseline low-risk (98.6% and 88.3%, respectively), intermediate-risk (94.9% and 61.8%, respectively) and high-risk (75.5% and 32.9%, respectively) cohorts. Follow-up data were even more discriminative, with 100%, 92% and 69% 1-year survival, respectively. The number of low-risk noninvasive criteria was also associated with survival. These analyses suggest that the ESC/ERS risk assessment may be applicable in patients with medically treated CTEPH. Copyright © ERS 2018."
}